Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Intralipid · 1 trial · 2 indications
Endothelium-dependent brachial artery flow-mediated dilation (FMD) was assessed. Ultrasound images of the brachial artery were obtained and arterial diameters were measured with customized software. Brachial artery FMD was calculated as (hyperemic diameter - baseline diameter)/baseline diameter × 100.
| Arm | Type | Description |
|---|---|---|
| Healthy Volunteer | ACTIVE_COMPARATOR | Subjects receive 24 hours of infusion of 0.9% normal saline, dextrose (sugar) without fat, ClinOleic (olive oil-based), and Intralipid (soybean-derived fat) |
| Name | Type | Description |
|---|---|---|
| Intralipid | DRUG | Infusion of Intralipid (soybean-derived fat) |
| ClinOleic | DRUG | Infusion of ClinOleic (olive oil-based) |
| Dextrose | DRUG | Infusion of dextrose (sugar) without fat |
| Saline (control) | OTHER | Infusion of 0.9% normal saline |
Inclusion Criteria: * Healthy males or females, BMI 25 - 35 kg/m2, between the ages of 18 and 65 years Exclusion Criteria: * The patient is pregnant or breast feeding * Subjects have or with history of diabetes, hypertension, fasting triglyceride levels \> 250 mg/dL, liver disease (ALT 2.5x \> up...
Intralipid is a soybean oil-based lipid emulsion being studied for metabolic diseases, specifically for its effects on insulin sensitivity. It is currently in Phase 2 clinical development as an investigational small molecule therapy. The drug is being evaluated in a completed clinical trial involving healthy volunteers.
Intralipid is a soybean oil-based lipid emulsion that is being studied for its effects on insulin sensitivity in metabolic diseases. The drug's mechanism involves the modulation of lipid metabolism, which is relevant to conditions such as insulin resistance. It is currently in Phase 2 clinical development.
Intralipid is being developed by Baxter International Inc., a company publicly traded under the ticker symbol BAX. The drug is currently in Phase 2 clinical development for metabolic diseases, with a focus on insulin sensitivity.
Intralipid is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug has completed one Phase 2 clinical trial, which was an active-controlled study involving 12 participants.
Intralipid has one completed clinical trial, NCT02185729, titled 'Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers.' This Phase 2 study enrolled 12 participants in the United States and was active-controlled, with a biomarker-selected design.
No, Intralipid is not the same as ClinOleic. Intralipid is a soybean oil-based lipid emulsion, while ClinOleic is an olive oil-based lipid emulsion. They were compared in a clinical trial (NCT02185729) to evaluate their effects on insulin sensitivity in healthy volunteers.